Laura Doni
Overview
Explore the profile of Laura Doni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roviello G, De Gennaro I, Vascotto I, Venturi G, DAngelo A, Winchler C, et al.
Genes (Basel)
. 2025 Jan;
16(1.
PMID: 39858553
Mutations of the von Hippel-Lindau () tumor suppressor gene occur frequently in clear cell renal cell carcinoma (RCC), the predominant histology of kidney cancer, and have been associated with its...
2.
Gambale E, Venturi G, Guarino A, Vascotto I, Pillozzi S, Desideri I, et al.
Cancer Diagn Progn
. 2024 Sep;
4(5):680-683.
PMID: 39238619
Background/aim: Cutaneous squamous cell carcinoma (SCC) is a common skin cancer with significant morbidity and mortality, particularly in advanced stages. Treatment options for metastatic cutaneous SCC in very elderly patients...
3.
Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, et al.
Clin Genitourin Cancer
. 2024 Jul;
22(5):102147.
PMID: 39030142
Introduction: The administration of proton pump inhibitors (PPIs) is a common practice to reduce gastro-esophageal adverse events associated with drug treatments but may impair absorption and exposure to oncology drugs....
4.
Bloise F, Manfredi F, Zatteri L, Dima G, Carli C, Di Vita R, et al.
Cells
. 2024 Jun;
13(11.
PMID: 38891093
The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone significant transformations in recent years. The introduction of novel combination therapies involving tyrosine kinase inhibitors (TKI) and immune checkpoint...
5.
Dini F, Susini P, Zuccaro B, Nisi G, Cuomo R, Grimaldi L, et al.
Melanoma Res
. 2024 Jun;
34(5):429-438.
PMID: 38833343
Eyelid melanoma (EM) is a malignant neoplasm accounting for around 1% of eyelid malignancies. Because of its rarity, most of our knowledge of EM is currently based on studies of...
6.
Gambale E, Maruzzo M, Messina C, De Gennaro Aquino I, Vascotto I, Rossi V, et al.
Clin Genitourin Cancer
. 2024 May;
22(4):102099.
PMID: 38776583
Background: Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in...
7.
Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, et al.
Clin Genitourin Cancer
. 2024 May;
22(4):102096.
PMID: 38759335
Prostate carcinoma (PC), the second most diagnosed cancer globally, saw approximately 1,414,000 new cases in 2020, with 17% being de novo metastatic. In these cases, the 5-year relative survival rate...
8.
De Giorgi V, Silvestri F, Cecchi G, Venturi F, Zuccaro B, Perillo G, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611072
Despite being early-stage tumors, thin cutaneous melanomas contribute significantly to mortality and have a rising incidence. A retrospective case-control study was performed to identify clinical-dermoscopic and histopathological variables linked to...
9.
Dini F, Susini P, Nisi G, Cuomo R, Grimaldi L, Massi D, et al.
Int J Dermatol
. 2024 Feb;
63(6):726-736.
PMID: 38351466
Periocular sebaceous carcinoma (PSC) is a rare, aggressive, and potentially metastatic adnexal malignancy. Due to the ability of PSC to resemble several benign and malignant conditions, diagnosis is often delayed...
10.
Catalano M, De Giorgi U, Bimbatti D, Buti S, Procopio G, Sepe P, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):514-522.e1.
PMID: 38296678
Background: Although in metastatic renal cell carcinoma (mRCC) patients with intermediate and poor risk the benefit of combination strategies versus tyrosine kinase inhibitor (TKI) has been ascertained, in those with...